Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Natural antitumor compounds described by Banyu

May 27, 1997

Inhibitors of 5alpha-reductase from Kyowa Hakko

May 27, 1997

Banyu discovers potent new antitumor agent

May 27, 1997

Glaxo Wellcome discloses heteroaromatic protein tyrosine kinase inhibitors

May 27, 1997

Panretin in AIDS-related Kaposi's sarcoma

May 26, 1997

Promising phase II results for thalidomide in brain cancer and Kaposi's sarcoma

May 23, 1997

Improved microtubule-inhibitory anticancer agents in development

May 23, 1997

NeoPharm reports on antisense liposomes which inhibit Raf-1 proteins

May 23, 1997

Oxford GlycoSciences receives U.K. approval to commence trials on novel nucleoside analogue

May 22, 1997

Enrollment complete for phase II trial of lisofylline in AML

May 22, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...